logo

Medicinova Inc (MNOV)



Trade MNOV now with
  Date
  Headline
7/29/2018 8:49:42 PM MediciNova Announces Full Enrollment In ALS Biomarker Clinical Trial
4/23/2018 6:02:38 AM Innovus Pharma Adds Ryan Selhorn As VP, CFO
4/13/2018 6:33:38 AM MediciNova Announces Presentation Of Positive Results From Interim Analysis Of Phase 2 Trial Of MN-001 (tipelukast)
3/29/2018 6:32:10 AM MediciNova Reports Results Of Phase 2 Clinical Trial Of MN-166 (ibudilast) In Methamphetamine Dependence
3/28/2018 9:10:29 PM MediciNova, Univ. Of Sydney Concord Cancer Centre To Evaluate MN-166 In CIPN
3/28/2018 8:34:02 PM B. Riley FBR Starts MediciNova Inc (MNOV) At Buy With $22 Price Target
1/31/2018 7:11:32 AM MediciNova Announces Presentation Of SPRINT-MS Phase 2b Study Of MN-166 In Progressive MS At The ACTRIMS Forum
11/10/2017 1:37:25 AM MediciNova Appoints Hideki Nagao To Its Board
10/26/2017 6:11:29 AM MediciNova Unveils Positive Top-Line Results From SPRINT-MS Phase 2b Trial Of MN-166 In Progressive MS
9/19/2017 6:02:16 AM MediciNova Completes Enrollment In Phase 2 Clinical Trial Of MN-166 (ibudilast) In Methamphetamine Dependence